摘要 : The unexpectedly low vaccine efficacy of Dengvaxia (R), developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism abo... 展开
作者 | Galula~ Jedhan Ucat Salem~ Gielenny M. Chang~ Gwong-Jen J. Chao~ Day-Yu |
---|---|
作者单位 | |
期刊名称 | 《Human vaccines & immunotherapeutics.》 |
总页数 | 9 |
语种/中图分类号 | 英语 / R392 |
关键词 | Dengue virus dengue virus-like particles maturity broadly neutralizing antibody |
馆藏号 | N2014022600059962 |